MDACC Study No:COGARST0921 ( NCT No: NCT01222715)
Title:A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
Principal Investigator:Winston Huh
Treatment Agent:Bevacizumab; Cyclophosphamide; Temsirolimus; Vinorelbine
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if it is feasible to give
vinorelbine and cyclophosphamide with either bevacizumab or temsirolimus to
patients with relapsed or refractory rhabdomyosarcoma (RMS). The safety of
these drug combinations will also be studied.

Vinorelbine is designed to block cancer cells from dividing.

Cyclophosphamide is designed to block cancer cells from dividing, which may
slow or stop their growth and spread throughout the body. This may cause the
cancer cells to die.

Bevacizumab is designed to block the growth of blood vessels, which may help to
slow or block the growth of cancer.

Temsirolimus is designed to block the growth of cancer cells, which may cause
cancer cells to die.

This study is called a clinical trial. A clinical trial is a research study
involving treatment of a disease in human patients. This study is organized by
Children’s Oncology Group (COG). COG is an international research group that
conducts clinical trials for children with cancer. More than 200 hospitals in
North America, Australia, New Zealand, and Europe are members of COG.
Hide details for General InformationGeneral Information

Disease Group:Pediatrics; Sarcoma
Phase of Study:Phase II
Treatment Agents:Bevacizumab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:The Children's Oncology Group (COG)
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Winston Huh
Dept: Pediatrics
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults